GT Biopharma, Inc.
No SEC Form 4 filings for $GTBP in the last 30 days.
See all $GTBP insider activity →GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000109657 0000109657 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
GT Biopharma (NASDAQ: GTBP) reported Q2 2026 results for the quarter ended June 30, 2026. It said Phase 1 TriKE candidates GTB-3650 (CD33+ leukemias) and GTB-5550 (B7-H3+ solid tumors) are enrolling, with updates expected in 2H 2026. Cash was about $5.1M, funding through Q4 2026. Q2 R&D was ~$1.1M, SG&A ~$3.4M, and net loss ~$4.5M.
GT Biopharma (NASDAQ: GTBP) says it has integrated AI tools into discovery and protein engineering for its tumor-targeting NK cell engagers and multi-domain proteins. The company expects efficiency gains that could move multiple new candidates into pre-IND development in 2027. Its TriKE-based programs include Phase 1 GTB-3650 (CD33) and GTB-5550 (B7-H3), with first patient dosed May 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning GTBP (GT Biopharma, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent GTBP coverage spans financial news, technology and corporate actions.
Shareholder approval of a reverse split and equity plan amendments can change near-term float, liquidity, and capital-markets expectations.
The update cadence and cash runway through Q4 2026 are the key near-term drivers for GTBP risk and valuation.
AI integration is positioned as an efficiency lever to generate additional pre-IND candidates, but the article provides no new clinical efficacy/safety data.
AI-driven workflow improvements could modestly de-risk pipeline execution, but the article provides no new clinical results or quantified milestones.
The announcement of enrollment updates for GTB-3650 Phase 1 trial indicates ongoing clinical development, which could positively influence investor sentiment and the stock's near-term performance.
alphai scores every news story that mentions GTBP with an AI model for sentiment and relevance, and aggregates insider trades from GT Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000109657 0000109657 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readGT Biopharma (NASDAQ: GTBP) reported Q2 2026 results for the quarter ended June 30, 2026. It said Phase 1 TriKE candidates GTB-3650 (CD33+ leukemias) and GTB-5550 (B7-H3+ solid tumors) are enrolling, with updates expected in 2H 2026. Cash was about $5.1M, funding through Q4 2026. Q2 R&D was ~$1.1M, SG&A ~$3.4M, and net loss ~$4.5M.
5 min readGT Biopharma (NASDAQ: GTBP) says it has integrated AI tools into discovery and protein engineering for its tumor-targeting NK cell engagers and multi-domain proteins. The company expects efficiency gains that could move multiple new candidates into pre-IND development in 2027. Its TriKE-based programs include Phase 1 GTB-3650 (CD33) and GTB-5550 (B7-H3), with first patient dosed May 2026.
6 min readGT Biopharma, a clinical-stage immuno-oncology company using its TriKE natural killer cell engager platform, said AI tools rolled out internally have improved discovery and drug engineering productivity. The company plans to advance lead programs GTB-3650 and GTB-5550 through Phase 1 studies this year and use AI for candidate selection, molecular design, and structural modeling. Shares were up 0.38% to $0.48 premarket, per Benzinga Pro.
4 min readGT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies ...
3 min readClinical-stage immuno-oncology company GT Biopharma Inc. ( NASDAQ:GTBP ) announced on Wednesday that enrollment in the dose escalation cohorts of the Phase 1 trial of GTB-3650 for relapsed or refractory CD33-expressing hematologic malignancies is on track.
3 min readSAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer ( NK ) cell engager TriKE® platform, ...
2 min readSAN FRANCISCO, CALIFORNIA, June 13, 2025 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer ( NK ) cell engager platform, ...
2 min readGT Biopharma completed dosing in Cohort 1 and began Cohort 2 of its Phase 1 trial for GTB-3650 with no safety concerns. Early data shows increased NK cell activity, indicating promising immune response from its TriKE cancer therapy.
3 min readSAN FRANCISCO, CALIFORNIA, May 14, 2025 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer ( NK ) cell engager platform, ...
2 min read
